Pfizer's oral antiviral drug was found to reduce the risk of hospitalization or death from COVID-19 by 89%, according to interim results from a mid-to-late-stage study announced by the company on Friday.
Why it matters: Antiviral drugs can be a key pandemic-fighting tool, as not everyone will get vaccinated against the virus and it may take years to fully inoculate people in certain countries — particularly given current gaps in global vaccine supplies.
- Pfizer CEO Albert Bourla said in a statement that these findings from the phase 2/3 study marked "a real game-changer in the global efforts to halt the devastation of this pandemic."
Details: Pfizer's antiviral pill, PAXLOVID (PF-07321332), was developed specifically to treat COVID-19, by blocking activity of the main enzyme the virus needs to multiply.
- This was co-administered with a low dose of ritonavir, which is widely used in combination treatments for HIV infection.
Of note: No deaths were reported in patients with COVID-19 who received PAXLOVID for the study, according to a Pfizer statement.
- 10 people who received a placebo died of the virus.
Be smart: Paxlovid’s results are very encouraging to a lot of researchers because, like Merck's COVID-19 pill, an easy-to-take oral drug that reduces severe illness and hospitalization will offer a way out of the pandemic, says Axios’ health care business reporter Bob Herman.
Yes, but: There are some caveats. Pfizer’s findings came through a corporate press release, not a peer-reviewed journal, and federal regulators haven’t had a chance to scrutinize the drug’s clinical trial data yet.
The big picture: Remdesivir, a drug investigated earlier to treat Ebola and other diseases, is currently the only antiviral approved for COVID-19 treatment in the U.S.
- PAXLOVID is one of several antiviral pills being developed to treat people after they've been diagnosed with the coronavirus.
- The U.K. on Thursday became the first country in the world to approve an antiviral pill designed specifically in response to COVID-19: British regulators approved molnupiravir, developed by Merck and Ridgeback Biotherapeutics to prevent or treat the virus.
What's next: Pfizer said it will submit the findings as part of its ongoing rolling submission to the FDA for emergency use authorization "as soon as possible."
